Lorazepam Injection
NDC 0641-6045
Product Information
Lorazepam is a NDA-approved product labeled by Hikma Pharmaceuticals Usa Inc.. This medication is used to treat anxiety. It is supplied as a injection for intramuscular; intravenous administration. This product entry covers the primary NDC 0641-6045 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0641-6045?
What are the uses of this product?
What are Active Ingredients of this product?
- LORAZEPAM 4 mg/mL - A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LORAZEPAM (UNII: O26FZP769L)
- LORAZEPAM (UNII: O26FZP769L) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- BENZYL ALCOHOL (UNII: LKG8494WBH)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1665188 - LORazepam 2 MG in 1 ML Injection
- RxCUI: 1665188 - 1 ML lorazepam 2 MG/ML Injection
- RxCUI: 1665188 - lorazepam 2 MG per 1 ML Injection
- RxCUI: 1665326 - LORazepam 4 MG in 1 ML Injection
- RxCUI: 1665326 - 1 ML lorazepam 4 MG/ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.